Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down After Analyst Downgrade

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s stock price gapped down before the market opened on Tuesday after BTIG Research lowered their price target on the stock from $40.00 to $21.00. The stock had previously closed at $18.95, but opened at $14.27. BTIG Research currently has a buy rating on the stock. Theravance Biopharma shares last traded at $14.0130, with a volume of 1,876,408 shares.

Several other research analysts have also recently commented on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd. Oppenheimer began coverage on shares of Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price objective for the company. HC Wainwright raised their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday. Finally, Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $25.40.

Insider Activity

In related news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the completion of the sale, the senior vice president directly owned 277,695 shares in the company, valued at approximately $5,206,781.25. This trade represents a 10.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Key Headlines Impacting Theravance Biopharma

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company announced a deep cost reduction and restructuring expected to cut the cost base by ~60% (about $70M) and generate roughly $60–$70M of annualized cash flow, which should materially extend runway. Theravance press release
• Positive Sentiment: Balance sheet and near-term cash outlook remain supportive: $326.5M cash at Q4 2025 and roughly $400M expected at end?Q1 2026 (including milestones); management said it’s highly confident of a $100M 2026 TRELEGY milestone. Theravance press release
• Neutral Sentiment: Board has accelerated a strategic review and engaged advisors (Lazard) to evaluate alternatives — including a possible sale — which creates execution uncertainty but could unlock value if a transaction or focused restructuring materializes. Reuters: strategic review
• Negative Sentiment: Phase 3 CYPRESS missed its primary endpoint (OHSA composite) for ampreloxetine in symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy — this removes the company’s lead late?stage asset and is the proximate cause of the sharp share decline. Theravance press release
• Negative Sentiment: Market reaction: shares plunged on the trial news, trading was briefly halted, and put buying surged (roughly a ~983% jump in put volume versus typical levels), signaling elevated downside hedging/speculation and continued volatility near term.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. Quarry LP acquired a new position in shares of Theravance Biopharma in the third quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 515 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares during the period. CIBC Private Wealth Group LLC boosted its holdings in shares of Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 4,662 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares during the last quarter. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Stock Performance

The company’s fifty day simple moving average is $19.35 and its two-hundred day simple moving average is $16.87. The stock has a market capitalization of $717.03 million, a P/E ratio of 24.74 and a beta of 0.17.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.